Navigation Links
Alere Inc. Announces Extension of Consent Solicitations Related to its 9.0% Senior Subordinated Notes Due 2016, 8.625% Senior Subordinated Notes Due 2018 and 7.875% Senior Notes Due 2016 and Increased Consent Fees
Date:6/7/2011

WALTHAM, Mass., June 7, 2011 /PRNewswire/ -- Alere Inc. (NYSE: ALR) (the "Company") announced today that it has extended the expiration dates for each of its previously announced consent solicitations relating to its 9.0% Senior Subordinated Notes due 2016 (the "9.0% Notes"), 8.625% Senior Subordinated Notes due 2018 (the "8.625% Notes") and 7.875% Senior Notes due 2016 (the "7.875% Notes," and, together with the 9.0% Notes and the 8.625% Notes, the "Notes").  In addition, the Company announced that it has increased the maximum aggregate fees payable to holders of the Notes as of the applicable record dates set forth in the solicitation documents, as supplemented (the "Solicitation Documents"), in connection with the consent solicitations.  The consent solicitations solicit the consents of the requisite holders of the Notes as of the applicable record dates set forth in the Solicitation Documents, in relation to certain amendments to the indentures governing the Notes (together, the "Proposed Modifications"), including amendments to the covenants in the indentures entitled "Limitations on Restricted Payments" in order to permit the Company to repurchase equity interests in the Company from time to time for aggregate cash consideration of up to $200.0 million and certain related modifications (the "Restricted Payments Amendments").

The consent solicitations will expire at 5:00 p.m., New York City time, on June 8, 2011, unless further extended or earlier terminated.  The consent solicitations were previously scheduled to expire at such time on June 7, 2011. The extension of the expiration date relates to both the consent solicitation with respect to proposed amendments and waivers relating to the setting of record dates for certain purposes under the indentures governing the Notes and the consent solicitation with respect to the Restricted Payments Amendments.'/>"/>

SOURCE Alere Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Alere Inc. Declares Dividend on its Series B Convertible Perpetual Preferred Stock
2. Alere to Attend the Deutsche Bank 36th Annual Health Care Conference on May 4, 2011
3. Alere Inc. Announces First Quarter 2011 Results
4. Alere Earns NCQA Health Information Products Certification for Health Information Line
5. Alere Previews Findings from Key Research Study on Medication Adherence at Integrated Benefits Institute Conference
6. Alere Inc. Announces Fourth Quarter 2010 Results
7. Alere to Attend the Lazard Capital Markets 7th Annual Healthcare Conference on November 17, 2010
8. Alere to Attend the Fifth Annual JMP Securities Healthcare Conference on September 28, 2010
9. Alere Inc. Announces Pricing of Senior Subordinated Notes Offering; Offering Size Increased to $400.0 Million
10. Alere Inc. Announces Offering of $350 Million of Senior Subordinated Notes
11. Alere and AirStrip Technologies - a Powerful Collaboration Brings Innovative Remote Patient Monitoring to Obstetrical Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Research and Markets  has announced the addition of the ... their offering. The Central Nervous System (CNS) ... of pharmaceuticals industry. The numbers of CNS disorders have increased ... to meet the market requirements. There has been steady to ... the past two decades. The market for CNS therapies is ...
(Date:8/29/2014)... , Aug. 29, 2014  United Therapeutics Corporation ... U.S. District Court for the District of ... in the company,s case against Sandoz, Inc. regarding United ... Peter Sheridan ruled that U.S. Patent No. 6,765,117 ... enjoined Sandoz from marketing its generic product until the ...
(Date:8/29/2014)... Aug. 29, 2014  Unilife Corporation ("Unilife" or "Company") ... that it intends to release its financial results for ... 30, 2014 after market trading ends on Tuesday, September ... conference call for 4:30 p.m. U.S. EDT on Tuesday, ... a.m. AEST), to review the Company,s financial results, commercial partnerships, ...
Breaking Medicine Technology:US CNS Disorders Drug Pipeline Insight 2014 2District Court Decision Received In Remodulin Patent Case 2Unilife Corporation to Announce Financial Results for Fiscal Year 2014 Fourth Quarter and Year End on Tuesday, September 9, 2014 2
... Barbara,Ann Karmanos Cancer Institute's Philip A. Philip, M.D., ... outcome,of one of the largest randomized phase III ... an education session about the,future of pancreatic cancer ... annual meeting in Chicago, IL. , The clinical ...
... - Data from first Phase 3 trial presented at ... 3 trial open the door for,patient recruitment in Europe ... 2007 --,Theratechnologies (TSX: TH) reported today that 26-week data ... were presented today in Toronto at ENDO, the 89th,annual ...
Cached Medicine Technology:Clinical Trial Results Change Standard of Care for Pancreatic,Cancer Patients, Future Therapies Discussed 2Clinical Trial Results Change Standard of Care for Pancreatic,Cancer Patients, Future Therapies Discussed 3Theratechnologies: TH9507 Phase 3 Clinical Update 2Theratechnologies: TH9507 Phase 3 Clinical Update 3
(Date:8/30/2014)... Market Research Report on Global ... professional and in-depth market survey on Global and ... the basic information of Cell Disruptor including its ... explores global and China’s top manufacturers of Cell ... and market share etc. The report further analyzes ...
(Date:8/30/2014)... 2014 Hundreds of Byetta lawsuits ( ... move forward in U.S. courts, Bernstein Liebhard LLP reports. ... July 31, 2014, Byetta and Bydureon (an extended-release version ... claims that allege the drugs caused pancreatitis, pancreatic cancer ... these claims are pending in a multidistrict litigation underway ...
(Date:8/30/2014)... Grand Rapids, MI (PRWEB) August 30, 2014 ... Michigan residents, Forefront Dermatology is expanding with the addition ... Mich. Dr. David Hammond who has provided leading-edge skin ... practice with Forefront Dermatology. , “As a doctor, ... care they deserve. Through partnering with Forefront Dermatology, I’m ...
(Date:8/30/2014)... In today’s world, a good night’s sleep has become ... apnea (a medical problem where the airway collapses during sleep ... the rest they need to face their daily challenges. ... million people in the United States alone have sleep apnea. ... of those treated, many cannot tolerate their prescribed medical device ...
(Date:8/30/2014)... 30, 2014 "My wife suffered neck, ... car accident," said one of two inventors from Bethel, ... her shoulder and neck area. She tried other pillows ... and pressure, assisting in comfort and providing extra sleep." ... CRADLE to support the head, neck and back comfortably. ...
Breaking Medicine News(10 mins):Health News:Cell Disruptor Industry Global and Chinese Analysis for 2009-2019 in New Research Report at ReportsnReports.com 2Health News:Cell Disruptor Industry Global and Chinese Analysis for 2009-2019 in New Research Report at ReportsnReports.com 3Health News:Cell Disruptor Industry Global and Chinese Analysis for 2009-2019 in New Research Report at ReportsnReports.com 4Health News:Byetta Lawsuits Move Forward, as Bernstein Liebhard LLP Notes Settlements in More than 80 Cases 2Health News:Byetta Lawsuits Move Forward, as Bernstein Liebhard LLP Notes Settlements in More than 80 Cases 3Health News:Expanding Care at the Forefront of Dermatology 2Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3
... regimen in most cancer treatments. Since it is a very ... with something more comfortable for the patient. ,Now ... off the ovary and stop the production of a female ... agonist achieves a normal action, often mimicking the action of ...
... that intake of cruciferous vegetables with a high ... against bladder cancer. ... such as broccoli, cauliflower, kale, turnips, collards, Brussels ... ,They apply their anti-oxidant effect through down regulation ...
... only affects to work, sleep and performance of other activities ... memory and your concentration. ,This is the ... Saifudin Rashiq at the University of Alberta. ,As ... Multidisciplinary Pain Centre in Edmonton, Canada, the researchers studied 24 ...
... Researchers based at the National Cancer Institute and ... an antioxidant predominately found in tomatoes , does ... fact, the researchers noted an association between beta-carotene, ... risk for aggressive prostate cancer. ,It ...
... of a type of kidney malignancy called renal cancer according ... and Women's Hospital in Boston found that women and men ... were about 30 percent less likely to develop renal cell ... who drank beer, wine or liquor. ,Jung Eun ...
... the Australian National Audit Office found that the Department ... 100,000 people with tuberculosis to enter Australia but frequently ... treatment, The Australian reports. ,People with inactive ... sometimes are permitted to enter Australia if they sign ...
Cached Medicine News:Health News:A Fresh Alternative to Painful Chemotherapy Developed in UK 2Health News:Risk of Bladder Cancer Reduced by Broccoli and Cauliflower 2Health News:Chronic Pain can Impair Memory and Concentration 2Health News:Tomatoes are Not So Effective in Preventing Prostate Cancer 2
The Sabre 2400 provides high power performance and key user features to meet today's demanding electrosurgical needs. It is an ideal general-purpose electrosurgical generator....
The ExcaliburPlus PC is the most powerful isolated ESU with 10,000 V PTP in spray coag....
Finesse II electrosurgical generator (100-120 VAC) utilizes a patented design that integrates the electrosurgical generator and smoke evacuation system into a single compact unit....
The Aaron 800-EU is designed and engineered to be the most reliable and durable desiccator available today....
Medicine Products: